DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Phase 1

Completed

Conditions: Recurrent Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Ruxolitinib
Drug: Paclitaxel

First Posted Date: 2014-01-22

Last Posted Date: 2021-04-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02041429

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Palbociclib
Drug: Aromatase Inhibitor

First Posted Date: 2014-01-20

Last Posted Date: 2024-02-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 162

Registration Number: NCT02040857

Locations: 🇺🇸
MGH/North Shore Cancer Center, Danvers, Massachusetts, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States

and more 7 locations

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 2

Terminated

Conditions: Merkel Cell Carcinoma
Skin Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2014-01-15

Last Posted Date: 2023-05-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02036476

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Enzalutamide + External Beam Rt For Prostate

Phase 2

Completed

Conditions: Intermediate Risk Prostate Cancer

Interventions: Drug: Enzalutamide
Radiation: External Beam Radiation

First Posted Date: 2014-01-07

Last Posted Date: 2023-05-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT02028988

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: abiraterone acetate

First Posted Date: 2013-12-31

Last Posted Date: 2024-11-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02025010

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States

and more 5 locations

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1

Completed

Conditions: KRAS Mutant Non-Small Cell Lung Cancer
Solid Tumors

Interventions: Drug: Palbociclib
Drug: PD-0325901

First Posted Date: 2013-12-30

Last Posted Date: 2024-03-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02022982

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

PET/CT-Assessment of Liver Tumor Ablation

Not Applicable

Completed

Conditions: Liver Neoplasms
Liver Tumor

Interventions: Diagnostic Test: N-13 ammonia or F-18 fluorodeoxyglucose
Diagnostic Test: PET scan

First Posted Date: 2013-12-23

Last Posted Date: 2020-03-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT02018107

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2013-11-13

Last Posted Date: 2024-03-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 147

Registration Number: NCT01982448

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Indiana University- Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 17 locations

Healthy Living After Cancer: Weight Management Pilot Study

Not Applicable

Completed

Conditions: Weight Loss Program After Cancer Diagnosis

Interventions: Behavioral: Immediate Weight Loss Program Group
Behavioral: Delayed Weight Loss Program Group

First Posted Date: 2013-11-08

Last Posted Date: 2016-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT01978899

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Tivozanib As Maintenance Therapy In GYN

Phase 2

Terminated

Conditions: Primary Peritoneal Carcinoma
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Tivozanib

First Posted Date: 2013-10-30

Last Posted Date: 2017-06-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01972516

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy